There are currently 92 clinical trials in Glendale, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Behavioral Research Specialists, LLC, Glendale Adventist Medical Center, Glendale Memorial Hospital and Health Center and Global Research Management. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
NCT06103877
Recruiting
A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Volunteers
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/20/2025
Locations: Behavioral Research Specialists, LLC, Glendale, California
Conditions: Obsessive-Compulsive Disorder
Register for Updates
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06381466
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/19/2025
Locations: Research Site, Glendale, California
Conditions: Dilated Cardiomyopathy
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Glendale, California
Conditions: Generalized Anxiety Disorder
Register for Updates
A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors
NCT05094336
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-nul... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/19/2025
Locations: California Research Institute, Glendale, California
Conditions: Advanced MTAP-null Solid Tumors
Register for Updates
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/18/2025
Locations: Kent W. Small, MD, AMC, Glendale, California
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Glendale, CA, Glendale, California
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Randomized Trial Comparing Immediate Vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Recruiting
Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surg... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/18/2025
Locations: Kent W. Small, MD, AMC, Glendale, California
Conditions: Epiretinal Membrane
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Glendale Adventist, Glendale, California
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: 84000531 - Sherman Medical Group, Inc, Glendale, California +1 locations
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
NCT06630117
Recruiting
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
02/13/2025
Locations: California Clinical Trials Medical Group managed by PAREXEL (Site 0002), Glendale, California
Conditions: Healthy
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Neumora Investigator Site, Glendale, California
Conditions: Major Depressive Disorder
Register for Updates